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BRIEF DEFINITIVE REPORT
The epigenetic regulator ATF7ip inhibits Il2
expression, regulating Th17 responses
Jun Hyung Sin1,2, Cassandra Zuckerman1,2, Jessica T. Cortez1,3, Walter L. Eckalbar4,5, David J. Erle4,5, Mark S. Anderson1,3,4, and
Michael R. Waterfield1,2
T helper 17 cells (Th17) are critical for fighting infections at mucosal surfaces; however, they have also been found to
contribute to the pathogenesis of multiple autoimmune diseases and have been targeted therapeutically. Due to the role of
Th17 cells in autoimmune pathogenesis, it is important to understand the factors that control Th17 development. Here we
identify the activating transcription factor 7 interacting protein (ATF7ip) as a critical regulator of Th17 differentiation. Mice
with T cell–specific deletion of Atf7ip have impaired Th17 differentiation secondary to the aberrant overproduction of IL-2 with
T cell receptor (TCR) stimulation and are resistant to colitis in vivo. ChIP-seq studies identified ATF7ip as an inhibitor of Il2
gene expression through the deposition of the repressive histone mark H3K9me3 in the Il2-Il21 intergenic region. These results
demonstrate a new epigenetic pathway by which IL-2 production is constrained, and this may open up new avenues for
modulating its production.
Introduction
Naive CD4+ T cells differentiate into effector T cells after they
encounter antigen presented by antigen-presenting cells within
the LN. There are at least five well-defined effector T cell line-
ages, including T helper 1 (Th1), Th2, T follicular helper cells,
regulatory T cells (T reg cells), and Th17 (Zhu et al., 2010). Th17
cells are unique in their requirement to control pathogens at
mucosal surfaces (Gaffen et al., 2014; Naglik et al., 2017). Th17
cells produce the cytokines IL-17A, IL-17F, and IL-22, which in
turn act on epithelial cells and innate immune cells to help clear
the infection. In addition to their function in the normal im-
mune system, Th17 cells have been found to be critical in the
pathogenesis of multiple autoimmune diseases (Liu et al., 2009;
Shen et al., 2009,; Jadidi-Niaragh and Mirshafiey, 2011; Langley
et al., 2014).
Over the last decade, multiple factors have been implicated in
the development and inhibition of Th17 cells. Both in vitro and
in vivo, the orphan nuclear receptor Rorγt transcription factor
has been found to be critical for the development of Th17 cells
(Ivanov et al., 2006). Multiple studies have shown that IL-2 is
critical for the induction and maintenance of T reg cells
(Fontenot et al., 2005; Setoguchi et al., 2005) while also in-
hibiting Th17 development (Laurence et al., 2007; Yang et al.,
2011). Interestingly, while IL-2 inhibits Th17 development, it
does not cause a dramatic decrease in the induction of Rorγt.
Due to IL-2’s ability to promote immune tolerance, under-
standing the factors that control Il2 expression may have clinical
relevance. One potential avenue to alter T cell Il2 production and
CD4+ effector T cell differentiation would be to modulate the
epigenetic state of the Il2-Il21 locus.
There has been a significant body of work characterizing the
effect of specific repressive histone modifications on effector
T cell development (Wang et al., 2016). While generation of the
repressive H3K27me3 histone mark in T cells relies on one
protein complex centered on the histone methyltransferase,
EZH2, there are multiple protein complexes required for the
generation of the repressive H3K9me3 histone mark (Schultz
et al., 2002; Kimura, 2013; Bulut-Karslioglu et al., 2014). One
open question in the field is whether proteins important in the
formation of H3K9me3 histone marks modulate helper T cell
differentiation. To this end, we sought to determine the poten-
tial role for activating transcription factor 7 interacting protein
(ATF7ip) secondary to ATF7ip’s expression in the immune sys-
tem and ATF7ip’s functional role in H3K9me3 formation.
ATF7ip (also known as MCAF1 or mAM) is an epigenetic
regulator involved in gene repression through promoting the
formation of the H3K9me3mark (Wang et al., 2001). Through its
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interactions with binding partners such as the histone methyl-
transferase SETDB1/ESET (Wang et al., 2001; Timms et al.,
2016), MBD1, and members of the human silencing hub com-
plex (Fujita et al., 2003; Ichimura et al., 2005; Minkovsky et al.,
2014; Tchasovnikarova et al., 2015), ATF7ip has been implicated
in the regulation of gene expression programs in retroviral si-
lencing, cellular senescence, cancer susceptibility, and immune
tolerance (Turnbull et al., 2010; Sasai et al., 2013; Waterfield
et al., 2014; Timms et al., 2016). At the molecular level, two
different functions have been reported for ATF7ip: (1) as an
essential cofactor in SETDB1 enzymatic activity and (2) in
SETDB1 nuclear localization (Wang et al., 2001; Timms et al.,
2016). To characterize the in vivo function of ATF7ip, we cre-
ated a conditional KO mouse to allow Cre-mediated deletion of
ATF7ip in specific cell types. Interestingly, we found that
T cell–specific deletion of ATF7ip resulted in a defect in Th17
differentiation. Furthermore, global gene expression studies
revealed that one cause of the Th17 defect in ATF7ip-deficient
T cells is secondary to the increased production of IL-2. Chro-
matin immunoprecipitation sequencing (ChIP-seq) for H3K9me3
in naive T cells further refined the mechanism of increased IL-
2 production by showing decreased deposition of H3K9me3 in the
Il2-Il21 intergenic region. These studies reveal a new role for
ATF7ip in promoting Th17 differentiation by epigenetic silencing
of Il2 gene expression.
Results and discussion
ATF7ip inhibits in vitro and in vivo Th17 differentiation
We hypothesized that ATF7ip may have a function in the im-
mune system secondary to the significant expression of Atf7ip
mRNA in the cells and tissues of the immune system in public
RNA expression databases (BioGPS; Fig. 1 A). Expression pro-
filing for Atf7ip mRNA in multiple tissues demonstrates the
highest expression in the spleen (Fig. 1, A and B), with signifi-
cant expression of Atf7ip in T and B cells (Fig. 1 A). Within CD4+
T cell subsets, Atf7ip was highly expressed in naive T cells
(CD62L+CD44−CD25−) and T reg cells with lower expression in
effector-memory CD4+ T cells (CD62L−CD44+; Fig. 1 C). Because a
cascade of changes in gene expression occur with T cell activa-
tion (Liao et al., 2013), we examined whether Atf7ip expression
levels change with T cell stimulation. Activation of the TCR of
naive T cells (CD62L+CD44−CD25−) with anti-CD3 antibodies,
alone or in combination with costimulation of the CD28 cor-
eceptor for the TCR, caused a decrease in Atf7ip mRNA expres-
sion (Fig. 1 D), suggesting that the release of negatively regulated
targets of ATF7ip may be important in T cell activation and
action.
To interrogate the potential in vivo function of ATF7ip in
T cells, a conditional deletion allele of mouse Atf7ip was created
using a targeting construct surrounding exon 2 of Atf7ip with
loxP Cre-recombination sites (Atf7ipfl/fl mice; Fig. S1, A and B).
Deletion of Atf7ip in the germline resulted in embryonic lethality
in mice (Fig. S1 C), consistent with previous work in Drosophila
(Koch et al., 2009). To examine the function of ATF7ip in T cells,
Atf7ipfl/fl mice were crossed to transgenic mice expressing Cre
recombinase from the CD4 promoter (CD4-Cre). Quantitative
PCR (qPCR) confirmed the deletion of Atf7ip mRNA in T cells
(Fig. S1 D), and Western blot confirmed deletion of ATF7ip
protein (Fig. S1 E). Extensive immune profiling in both CD4-Cre/
Atf7ip+/fl T cells and CD4-Cre/Atf7ipfl/fl T cells indicated no dif-
ferences in steady-state thymic T cell subsets (Fig. S1 F), T reg
cells, or LN (Fig. S1 G)/spleen (not depicted) naive and activated/
memory T cells. To interrogate T cell lineage commitment in the
absence of ATF7ip, in vitro T cell differentiation assays were
performed. Interestingly, naive T cells from CD4-Cre/Atf7ipfl/fl
mice were unable to differentiate into IL-17A–producing Th17
cells despite normal induction of INFγ+ Th1 cells, IL-13+ Th2
cells, and Foxp3+ induced T reg cells (iT reg cells; Fig. 1, E–H).
The Th17 differentiation defect did not appear to be due to a loss
of RORγt (Fig. 1 I) or a defect in cell proliferation (Fig. S2, A and
B). Taken together, these data indicated a role for ATF7ip in Th17
effector differentiation.
In vivo, Th17 cells have been implicated in the development
of multiple autoimmune diseases (Patel and Kuchroo, 2015). In
mice, one well-characterized model of Th17-mediated colitis is
anti-CD3 colitis (Esplugues et al., 2011; Rutz et al., 2015). After
injection of anti-CD3, CD4-Cre/Atf7ipfl/fl mice had a lower per-
centage and absolute number of IL-17A+ Th17 cells in the small
intestine than CD4-Cre/Atf7ip+/fl mice (Fig. 2, A and B), with
equal numbers of INFγ+ Th1 cells and Foxp3+ T reg cells in the
mesenteric LNs (Fig. S2, C and E) and small intestine (Figs. 2 A
and S2, D and F). Furthermore, serum from CD4-Cre/Atf7ipfl/fl
mice revealed significantly less IL-17A than serum from CD4-
Cre/Atf7ip+/fl mice (Fig. 2 C), and the diminished Th17 response
in CD4-Cre/Atf7ipfl/fl mice correlated with less pathological in-
testinal inflammation (Fig. 2, D and E). The significance of AT-
F7ip in Th17 pathology was further confirmed in a second model
using a T cell transfer model of colitis (Ostanin et al., 2009).
Consistent with the results of the CD3-induced colitis model, we
found that Rag1−/− mice that received RBhi CD4-Cre/Atf7ipfl/fl
T cells did not lose weight, had reduced numbers of Th17 cells in
the colon, and had less intestinal pathology (Fig. 2, F and G; and
Fig. S2, G and H). Collectively, these data suggest that ATF7ip is
required for in vivo Th17-mediated inflammation.
ATF7ip-deficient T cells produce increased IL-2 under
Th17-inducing conditions
We next turned to the mechanism by which ATF7ip promotes
appropriate Th17 differentiation. Secondary to ATF7ip’s role in
the formation of the H3K9me3 histone mark, we hypothesized
that deletion of Atf7ip in T cells may allow for the aberrant
overexpression of an inhibitor of Th17 differentiation. To gain
insight into the altered gene regulation in CD4-Cre/Atf7ipfl/fl
T cells, global gene expression analysis with RNA sequencing
(RNA-seq) was performed in naive T cells and T cells in vitro
differentiated under Th17-polarizing conditions for 24 and 72 h
to capture early and late changes in gene expression (Fig. S3 A).
Consistent with ATF7ip’s function in gene repression, there
were more genes up-regulated in CD4-Cre/Atf7ipfl/fl T cells than
CD4-Cre/Atf7ip+/fl T cells in all three RNA-seq conditions (Fig. 3
A). A previous study of ATF7ip deletion in HeLa cells implicated
ATF7ip in silencing zinc finger proteins (Timms et al., 2016). In
line with this study, CD4-Cre/Atf7ipfl/fl naive T cells had several
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Figure 1. ATF7ip is required for in vitro Th17 differentiation. (A) Relative expression of Atf7ip mRNA in tissues and immune cells downloaded from the
BioGPS expression database. Red bars highlight hematopoietic cells or T cells. (B–D) Relative expression of Atf7ip mRNA in mouse tissues (B), CD4+ T cell
subsets (C), or naive CD4+ T cells (D) stimulated with either anti-CD3 (2 µg) or both anti-CD3 (2 µg) and anti-CD28 (2 µg) for the indicated times. (E–H) Naive
T cells from CD4-Cre/Atf7ip+/fl (Atf7ip+/fl) and CD4-Cre/Atf7ipfl/fl (Atf7ipfl/fl) mice were in vitro differentiated under Th17 (E), Th1 (F), iT reg cell (G), or Th2 (H)
conditions and analyzed for intracellular cytokine or Foxp3 expression. (I) Rorγt protein expression under Th17 conditions. A histogram of Rorγt expression
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zinc finger protein genes that were significantly overex-
pressed (false discovery rate [FDR] <0.01) compared with
CD4-Cre/Atf7ip+/fl naive T cells (Fig. 3 A). Interestingly, at 24 h
of Th17-inducing conditions, CD4-Cre/Atf7ipfl/fl T cells ex-
pressed more Il2 mRNA than CD4-Cre/Atf7ip+/fl T cells (Fig. 3
A). Consistent with IL-2’s known function in the maintenance
of T reg cells. At 72 h of Th17-inducing conditions, CD4-Cre/
Atf7ipfl/fl T cells had a gene signature more in line with T reg
cells, with a significant increase in Foxp3 expression along
with several genes associated with the T reg cell lineage
(Lrrc32, Socs2, Izumo1r, and Capg) and IL-2 signaling (Stat5a;
Fig. 3 A; Zemmour et al., 2018). Moreover, CD4-Cre/Atf7ipfl/fl
T cells compared with CD4-Cre/Atf7ip+/fl T cells had a signif-
icant decrease in many Th17-associated genes (Il17a, Ccl20, Il21,
Hif1a, and Rorc; Fig. 3 A). To confirm these findings, we also
performed qPCR on differentially expressed genes from the
RNA-seq data along with other genes in the Th17 pathway (Fig.
S3 B). Consistent with the modest decrease in Rorγt protein
expression in CD4-Cre/Atf7ipfl/fl T cells (Fig. 1 I), qPCR did not
reveal a decrease in Rorc at early time points.
under Th0 conditions is included for reference. Each data point in D–H represents an individual mouse with three mice per genotype. Data are representative of
five (E) or two (B–D and F–I) independent experiments. Error bars in B and C show mean with SEM of technical replicates. Error bars (D–H) show mean with
SD. **, P < 0.01 by Student’s t test.
Figure 2. Atf7ip deletion attenuates colitis in vivo. (A–E) CD4-Cre/Atf7ip+/fl (Atf7ip+/fl) and CD4-Cre/Atf7ipfl/fl (Atf7ipfl/fl) mice were injected intraperitoneal
with anti-CD3 antibodies and analyzed 48 h after injection. (A) Flow cytometric analysis of CD4+IL17A+INFγ+ small intestine IELs. (B) Percentage and absolute
numbers intraepithelial CD4+ T cells in the small intestine expressing IL-17A. (C) Serum IL-17A levels measured by ELISA. (D) Histological score of the small
intestine. (E) H&E staining of the small intestine. Bars, 100 µm. (F)Weight change in Rag1−/− recipients of RBhi naive T cells from either CD4-Cre/Atf7ip+/fl or
CD4-Cre/Atf7ipfl/fl mice measured on day 0, 14, 21, 28, 35, and 42. Results are the combination of two experiments with 13 mice per genotype. (G) Absolute
number of CD4+IL17A+ T cells in the colonic lamina propria of Rag1−/− mice. Each data point in B–D and G represents an individual mouse. Data are the
combination of three (B) or two (C, D, F, and G) independent experiments with three to four mice per group in each experiment. Error bars in B–D and G are
mean with SD. Error bars in F are SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001; significance by Student’s t test (B, C, and G); Mann–Whitney nonparametric test
(D); and two-way ANOVA followed by multiple t tests using the Holm–Sidak method (F).
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Figure 3. CD4-Cre/Atf7ipfl/fl T cells have increased Il2 and a decreased Th17 gene signature secondary to less H3K9me3 at the Il2-Il21 intergenic
region. (A) Volcano plots from RNA-seq data comparing global gene expression analysis of T cells from CD4-Cre/Atf7ipfl/fl mice and CD4-Cre/Atf7ip+/fl mice. Left
plot represents naive T cells, middle plot is T cells differentiated for 24 h under Th17-inducing conditions, and right plot is 72 h of Th17-inducing conditions. Red
numbers indicate the number of genes that are significantly increased (FDR <0.01) in CD4-Cre/Atf7ipfl/fl T cells, and blue numbers indicate the number of genes
that are significantly increased in CD4-Cre/Atf7ip+/fl T cells. RNA-seq was performed in triplicate for each condition. (B) Naive T cells from CD4-Cre/Atf7ip+/fl
(Atf7ip+/fl) and CD4-Cre/Atf7ipfl/fl (Atf7ipfl/fl) mice were in vitro differentiated for 4 d under Th17-inducing conditions (IL-6 + TGFβ) and analyzed by flow
cytometric analysis for intracellular cytokines (IL-17A, IL-2) or Foxp3. (C) Summary of flow cytometric data in B. (D) ELISA of secreted cytokines (IL-17A, IL-2,
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We next sought to determine if these transcriptional
changes also correlated with altered protein production. First,
we performed intracellular cytokine staining (ICS) for IL-2 in
differentiating T cells. As shown in Fig. 3 B, we found that
under Th17-inducing conditions, CD4-Cre/Atf7ipfl/fl T cells
produce more IL-2 and less IL-17A than CD4-Cre/Atf7ip+/fl
T cells. Furthermore, CD4-Cre/Atf7ipfl/fl T cells have increased
intracellular Foxp3 and secrete increased IL-2 and less IL-17A,
IL-17F, and IL-21 as measured by ELISA (Fig. 3, B–D). Alter-
native induction of Th17 cells can be also achieved by the
combination of IL-6, IL-23, and IL-1 to produce pathogenic
Th17 cells, so named due to their role in neuroinflammation
(Ghoreschi et al., 2010). CD4-Cre/Atf7ipfl/fl T cells cultured
with IL-6, IL-1, and IL-23 produce less IL-17A/IL-17F and in-
creased IL-2 by ICS and ELISA (Fig. S3, C–E). Altogether, these
data indicate that under a variety of Th17-inducing conditions,
CD4-Cre/Atf7ipfl/fl T cells produce increased IL-2 and de-
creased IL-17A.
ATF7ip is required for H3K9me3 deposition at the Il2-Il21
intergenic region
To gain further insight into the mechanism of increased IL-2
production in CD4-Cre/Atf7ipfl/fl T cells, we next explored the
potential epigenetic effect of ATF7ip broadly and on the Il2 locus
by performing ChIP-seq on T cells using an antibody directed to
the H3K9me3 mark. H3K9me3 ChIP-seq was performed in du-
plicate on naive T cells from both CD4-Cre/Atf7ip+/fl mice and
CD4-Cre/Atf7ipfl/fl mice and yielded ∼67,000 H3K9me3 active
sites in both genotypes, indicating that there was not a profound
reduction of H3K9me3 in naive CD4-Cre/Atf7ipfl/fl T cells (Fig. S3
F). In agreement with the ChIP-seq data, Western blot did not
reveal a reduction of H3K9me3 in CD4-Cre/Atf7ipfl/fl T cells
compared with CD4-Cre/Atf7ip+/fl T cells (Fig. S3 G).
Although there was not a global difference in H3K9me3, hi-
erarchical clustering showed that the samples clustered by
genotype (Fig. S3 H). Interestingly, there were 494 sites with a
twofold increase in H3K9me3 deposition in CD4-Cre/Atf7ip+/fl
naive T cells compared with CD4-Cre/Atf7ipfl/fl naive T cells,
while there were only 64 sites with a twofold increase in CD4-
Cre/Atf7ipfl/fl naive T cells (Fig. 3 E). These results support a role
for ATF7ip in promoting the formation of the H3K9me3 mark at
specific genomic locations in naive T cells. Consistent with prior
work in HeLa cells, a large number of zinc finger genes had a
significant decrease in H3K9me3 in CD4-Cre/Atf7ipfl/fl naive
T cells relative to CD4-Cre/Atf7ip+/fl T cells (Fig. 3, E and G).
Moreover, there was also a site of H3K9me3 deposition
of ∼1,200 bp in length located on chromosome 3 with a twofold
decrease of H3K9me3 (Fig. 3 E). This site is within the Il2-Il21
intergenic region, and ChIP-seq tracings showed a reduction of
the H3K9me3 histone mark in this region (Fig. 3 F). H3K9me3
ChIP qPCR confirmed that there was less H3K9me3 within this
region (Fig. 3 H). Consistent with increased IL-2 signaling, RNA-
seq showed increased Stat5 gene expression in CD4-Cre/Atf7ipfl/fl
T cells differentiated for 72 h in Th17-inducing conditions (Fig. 3
A). The increased Stat5 gene expression is unlikely secondary to
direct regulation of Stat5 because H3K9me3 ChIP-seq did not
show a reduction of H3K9me3 in the Stat5a or Stat5b locus (Fig.
S3 I). Together, these results suggest that naive CD4-Cre/
Atf7ipfl/fl T cells may be primed to produce more IL-2 secondary
to decreased repression by H3K9me3.
ATF7ip-deficient T cells produce increased IL-2 with TCR
stimulation
Our ChIP-seq data suggested that ATF7ip might inhibit Il2 gene
transcription through the deposition of H3K9me3 in the Il2-Il21
intergenic region. The data shown indicate increased IL-2 pro-
duction in CD4-Cre/Atf7ipfl/fl T cells under Th17-inducing con-
ditions; however, we hypothesized that CD4-Cre/Atf7ipfl/fl T cells
would produce increased IL-2 solely with TCR/CD28 engage-
ment, as naive CD4-Cre/Atf7ipfl/fl T cells have less H3K9me3 in
the Il2-Il21 intergenic region. Treatment of CD4-Cre/Atf7ipfl/fl
T cells with anti-CD3 or anti-CD3/anti-CD28 resulted in in-
creased levels of Il2 mRNA and IL-2 protein as measured by ICS
and ELISA (Fig. 4, A–D). Furthermore, in vivo treatment of CD4-
Cre/Atf7ipfl/fl mice with anti-CD3 resulted in an increased per-
centage and number of IL-2–producing T cells in the mesenteric
LN and small intestine intraepithelial lymphocytes (IELs; Fig. 4,
E–H).
To determine if the increased IL-2 production by CD4-Cre/
Atf7ipfl/fl T cells would affect other CD4+ T h cell lineages, we
performed in vitro T cell differentiation assays in the presence
or absence of IL-2. Interestingly, there was equally effective
induction of INFγ+ Th1 cells (Fig. 5 A) and IL-13+ Th2 cells (Fig. 5
B) with or without the addition of IL-2. These results indicate
that both CD4-Cre/Atf7ip+/fl T cells and CD4-Cre/Atf7ipfl/fl T cells
produce sufficient IL-2 for effective Th1 and Th2 differentiation.
In the absence of IL-2, iT reg cell induction was increased in CD4-
Cre/Atf7ipfl/fl T cells compared with CD4-Cre/Atf7ip+/fl T cells,
consistent with IL-2’s known role in T reg cell function (Fig. 5 C).
Prior studies have shown that the cytokines IL-2, IL-4, and IL-12
can negatively regulate IL-2 production, and this inhibition is
dependent on Stat5 (Villarino et al., 2006, 2007). As human IL-2
was added to Th1, Th2, and iT reg cell culture conditions, we
expected to see an inhibition of endogenous IL-2 production
IL-17F, and IL-21) from Th17 culture supernatant. (E–G) ChIP-seq data for H3K9me3 from CD4-Cre/Atf7ip+/fl (Atf7ip+/fl) and CD4-Cre/Atf7ipfl/fl (Atf7ipfl/fl) naive
T cells performed in duplicate. (E) Scatterplot comparing log2 fold change of H3K9me3 in CD4-Cre/Atf7ip+/fl (Atf7ip+/fl) and CD4-Cre/Atf7ipfl/fl (Atf7ipfl/fl) naive
T cells. Blue numbers represent the number of loci with twofold increased H3K9me3 in CD4-Cre/Atf7ip+/fl naive T cells compared with CD4-Cre/Atf7ipfl/fl
naive T cells. Red numbers indicate the number of loci with twofold increased H3K9me3 in CD4-Cre/Atf7ipfl/fl naive T cells. (F) Integrated genome viewer
H3K9me3 ChIP-seq tracings for the Il2-Il21 intergenic region. (G) Integrated genome viewer H3K9me3 ChIP-seq tracings for the indicated zinc finger proteins
(Zfp). Green boxes show sites of twofold decreased H3K9me3 deposition. (H) H3K9me3 ChIP qPCR targeting the site of H3K9me3 deposition within the Il2-Il21
intergenic region and within the Zfp780b gene. Each data point represents an individual mouse. Data in B and C are one representative experiment of three
experiments with three mice per group. Data in D are the combination of three experiments with two to three mice per group. Error bars are mean with SD
(C and D) and mean and SD of technical replicates (H). *, P < 0.05; **, P < 0.01; ***, P < 0.001 by Student’s t test.
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Figure 4. CD4-Cre/Atf7ipfl/fl T cells produce increased IL-2 with TCR stimulation. Naive T cells were stimulated for 12–24 h in the presence of TCR
stimulation (2 µg anti-CD3) or with both TCR stimulation (2 µg anti-CD3) and costimulation (2 µg anti-CD28). (A) qPCR for Il2mRNA. (B) Flow cytometric data
for IL-2 with ± SD shown. (C and D) IL-2 ELISA from culture supernatant. (E and G) Representative flow cytometry of IL-2 expression in the mesenteric LN (E)
or small intestine IELs (G) 48 h after in vivo anti-CD3 treatment. (F and H) Summary of flow cytometry data from the mesenteric LN (E) and small intestine (SI)
IELs (G). Each data point represents an individual mouse. Data in A and B are representative of two experiments with three mice per genotype. Data in C, D, F,
and H are the combination of three experiments with three to four mice per genotype. Error bars are SEM (A) and mean with SD (B–D, F, and H). *, P < 0.05;
***, P < 0.001 by Student’s t test.
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during differentiation; however, CD4-Cre/Atf7ipfl/fl T cells pro-
duced increased Il2 mRNA (Fig. S3 J) and IL-2 protein (Fig. 5,
D–F) compared with CD4-Cre/Atf7ip+/fl T cells during in vitro
differentiation into the Th1, Th2, and iT reg cell lineages. These
results indicate that CD4-Cre/Atf7ipfl/fl T cells are able to at least
partially overcome cytokine repression of Il2 gene expression
and further support our data that the Il2 locus in CD4-Cre/
Atf7ipfl/fl T cells is in a less repressed conformation.
Finally, we attempted to confirm that the defect in Th17
generation in CD4-Cre/Atf7ipfl/fl T cells was secondary to aber-
rant IL-2 production by performing cell mixing and IL-2 block-
ing studies. An in vitro Th17 differentiation was performed,
mixing WT T cells homozygous for the congenic marker Thy1.1
with equal numbers of either CD4-Cre/Atf7ipfl/fl T cells or CD4-
Cre/Atf7ip+/fl T cells homozygous for the congenic marker
Thy1.2. In support of a secreted factor causing the Th17 defect,
CD4-Cre/Atf7ipfl/fl T cells were able to suppress IL-17A produc-
tion in trans from WT T cells, whereas CD4-Cre/Atf7ip+/fl T cells
had no effect on IL-17A production fromWT T cells (Fig. 5, G and
H). To confirm that IL-2 is the cause of the Th17 defect, coculture
experiments were performed in the presence of the IL-2 block-
ing antibody S4B6 or an isotype control antibody (Fig. 5, G and
H). In agreement with previous studies, IL-2 blockade with S4B6
increased the percentage of IL-17A–producing T cells in all
conditions (Laurence et al., 2007). Interestingly, treatment with
S4B6 was able to rescue the trans IL-17A defect seen in WT
T cells cocultured with CD4-Cre/Atf7ipfl/fl T cells, while the iso-
type control antibody had no effect (Fig. 5 G, green box). This
result further implicates increased secretion of IL-2 as a po-
tential mechanism for the Th17 defect seen in CD4-Cre/Atf7ipfl/fl
T cells. While IL-2 blockade was able to rescue the trans defect,
S4B6 treatment was unable to completely rescue IL-17A pro-
duction directly in Thy1.2+CD4-Cre/Atf7ipfl/fl T cells. The partial
rescue is likely due to IL-2’s known autocrine function and the
inability of the blocking antibody to act before IL-2 binding its
receptor. Together, these results implicate increased IL-2 pro-
duction as one potential mechanism for the Th17 defect seen in
CD4-Cre/Atf7ipfl/fl T cells.
This work establishes a new function for ATF7ip in silencing
Il2 gene expression in T cells through promoting the deposition
of H3K9me3 in the Il2-Il21 intergenic region. Prior work has
shown a role for H3K9me3 in silencing II2 in both anergic T cells
(Bandyopadhyay et al., 2012) and Th17 cells through the tran-
scription factor Aiolos (Quintana et al., 2012); however, this
study is the first to implicate H3K9me3 in silencing Il2 gene
expression in naive T cells. As Atf7ipmRNA levels decrease with
TCR stimulation, we propose a model by which loss of Atf7ip
results in decreased H3K9me3 at the Il2 locus and a more open
chromatin conformation allowing the robust IL-2 production
necessary for a productive immune response. In ATF7ip-
deficient T cells, Il2 gene expression is not effectively silenced,
causing the overproduction of IL-2 and the in vitro inhibition of
Th17 differentiation. Moreover, the enhanced IL-2 production in
ATF7ip-deficient T cells and decreased IL-21 production (Fantini
et al., 2007) caused CD4-Cre ATF7ipfl/fl mice to be resistant to
Th17-mediated colitis in vivo. IL-2 has previously been reported
as an inhibitor of Th17 differentiation through the direct action
of STAT5 on the Il17a locus (Laurence et al., 2007; Yang et al.,
2011). Interestingly, these studies showed that while IL-2 caused
a Th17 defect, there was not a significant decrease in Rorγt
protein. These results are consistent with our data showing only
a modest defect in Rorγt production in ATF7ip-deficient T cells.
Secondary to the overproduction of IL-2, CD4-Cre ATF7ipfl/fl
mice might have been expected to have increased numbers of T
reg cells. Under steady-state conditions, we found no difference
in the percentage or absolute number of T reg cells in CD4-Cre
ATF7ip+/fl mice compared with CD4-Cre ATF7ipfl/fl mice. We saw
a trend for increased T reg cells in the small intestine and
mesenteric LN of ATF7ip-deficient mice during anti-CD3 colitis;
however, this did not reach statistical significance. ATF7ip de-
ficiency may increase T reg cell numbers through IL-2 overpro-
duction in other inflammatory conditions or autoimmune prone
mice, and future studies will examine these possibilities.
In CD4+ T cells, ATF7ip is important in regulating the Il2-Il21
intergenic region along with multiple other genomic regions.
RNA-seq and ChIP-seq performed in ATF7ip-deficient T cells
show that ATF7ip is critical for silencing zinc finger proteins in
addition to Il2. A study of ATF7ip-deficient HeLa cells also found
that ATF7ip regulated zinc finger proteins, suggesting that
ATF7ip has similar functions in diverse cell types (Timms et al.,
2016). ATF7ip partners with the histone methyltransferase
SETDB1, and the two proteins exert similar effects in HeLa cells
with regard to the silencing of zinc finger proteins (Timms et al.,
2016). Interestingly, T cell–specific deletion of SETDB1 causes a
block in thymic T cell development (Takikita et al., 2016) and
augmented Th1 priming (Adoue et al., 2019), while our data
show no effect on thymic T cell development or Th1 differenti-
ation. These results imply nonredundant roles for SETDB1 and
ATF7ip, and further workwill be needed to parse the differential
roles of these two epigenetic factors in T cells.
Figure 5. iT reg cell induction is augmented in Atf7ipfl/fl T cells and Atf7ipfl/fl T cells suppress IL-17A production in trans. (A–C) Naive T cells from
CD4-Cre/Atf7ip+/fl (Atf7ip+/fl) and CD4-Cre/Atf7ipfl/fl (Atf7ipfl/fl) mice were in vitro differentiated in the presence (+IL-2) or the absence (no IL-2) of IL-2 under Th1
(A), Th2 (B), or iT reg cell (C) conditions and analyzed for intracellular cytokine or Foxp3 expression. (D–F) Naive T cells from CD4-Cre/Atf7ip+/fl (Atf7ip+/fl) and
CD4-Cre/Atf7ipfl/fl (Atf7ipfl/fl) mice were in vitro differentiated in the presence (+IL-2) or the absence (no IL-2) of IL-2 under Th1 (D), Th2 (E), or iT reg cell (F)
conditions and analyzed for IL-2 expression. (G and H)WT (Thy1.1) naive T cells were mixed at a 50:50 ratio with either CD4-Cre/Atf7ip+/fl (Thy1.2) or CD4-Cre/
Atf7ipfl/fl (Thy1.2) naive T cells and cultured for 96 h under Th17-inducing conditions with the addition of no IL-2 blocking antibody (No Antibody), 5 µg isotype
control antibody (Isotype), or 5 µg S4B6. (G) Flow cytometric analysis of T cells expressing Thy1.1, Thy1.2, and IL-17A. Green box shows that S4B6 is able to
rescue the trans defect in IL-17A production. (H) Summary of flow cytometric data. Each data point represents an individual mouse. Each data point in A–F and
H represents an individual mouse. Data are representative of two independent experiments (A and D) or one of two experiments (B, C, E, and F) with three mice
per group; data in G and H are representative of two experiments with two to four mice per genotype. Error bars (A–F and H) show mean with SD. *, P < 0.05;
**, P < 0.01; ***, P < 0.001 by Student’s t test.
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Our work clearly shows that one locus critically regulated
by ATF7ip is the Il2-Il21 intergenic region. IL-2 is a pleotropic
cytokine with effects in both effector T cell differentiation and
the prevention of autoimmunity. Small nucleotide poly-
morphisms found in the Il2-Il21 intergenic region are linked to
multiple autoimmune diseases, including rheumatoid arthri-
tis (Zhernakova et al., 2007), lupus (Sawalha et al., 2008),
inflammatory bowel disease (Festen et al., 2009), celiac dis-
ease (van Heel et al., 2007), multiple sclerosis (Matesanz et al.,
2001), Graves’ disease (Todd et al., 2007), and type 1 diabetes
(Cooper et al., 2008). These small nucleotide polymorphisms
are hypothesized to lead to attenuated IL-2 production and a
susceptibility to autoimmune disease. Due to the possibility
that low IL-2 levels play a part in the pathogenesis of auto-
immunity, low dose IL-2 therapy has gained momentum as a
treatment for multiple autoimmune diseases secondary to its
positive effect on T reg cells and its inhibition of Th17 and T
follicular helper cells (Klatzmann and Abbas, 2015; Abbas
et al., 2018). Furthermore, inhibitors of specific epigenetic
pathways are in clinical trials for cancer (Biswas and Rao,
2018), and thus one could envision modulating epigenetic
pathways to target autoimmunity. Future work will deter-
mine if inhibitors of ATF7ip could be used therapeutically to




Atf7ipfl/fl mice were generated by creating a targeting vector
using the pEasyflox-DTA backbone (gift of Dr. Ralf Kuhn, Insti-
tute for Developmental Genetics, Helmholtz Center Munich,
German Research Center for Environmental Health, Munich,
Germany). Homology arms were PCR amplified from bacterial
artificial chromosome C57BL/6 ES cell genomic DNA obtained
from the Children’s Hospital Oakland Research Institute. The 59
arm was amplified using primers 59-GTAGGTGAAATGGTTTGA
GAG and 39-GACTTTTCACGCCCCTGAAG to amplify a 5,026-bp
PCR product. The 39-arm was amplified using primer’s 59-GTC
CATCTGGGGACACGCTGTTG and 39-GACTCAGCAGTGCTGCTT
GC to amplify a 3,294-bp PCR product. The critical exon was
amplified using primers 59-CGGCTCCTTTTTAACTCTTC and 39-
GAAGAACTAATGTGTCGTC to amplify a 2,171-bp product. PCR
products were sequenced and then cloned into pEasyflox-DTA
using In-Fusion (Takara) one-step cloning. The targeting con-
struct was linearized with Not1 and electroporated into
JM8A3.N1 (C57BL/6-derived) ES cell line by the University of
California San Francisco (UCSF) ES Cell Targeting Core. ES cell
colonies were digested with BamHI, and colonies were screened
by Southern blot using a 370-bp probe amplified using primers
59-GTGATGTTTCTCCCAGCGTG and 39-TTCCTTTGACTTCCA
CCGTG. Targeted ES cells were microinjected into blastocysts by
the UCSF Gladstone Transgenic Gene-Targeting Core. Male
chimeras were bred to C57BL/6 females (the Jackson Laboratory;
#000664), and agouti pups were screened by PCR for germline
transmission. The neomycin cassette was removed by breeding
to B6.Cg-Tg(Pgk1-flpo)10Sykr/J, a mouse strain that expresses
flippase recombinase under control of the phosphoglycerate
kinase 1 gene (the Jackson Laboratory; #011065). B6.Cg-Tg(Zp3-
cre)1Gwh/J were purchased from the Jackson Laboratory
(#006888). CD4-Cre and Foxp3-GFP mice were provided by Jeff
Bluestone (University of California, San Francisco, San Fran-
cisco, CA). B6.Thy1.1 mice were purchased from the Jackson
Laboratory (#000406). B6.129S7-Rag1tm1Mom/J were pur-
chased from the Jackson Laboratory (#002216). Mice were
maintained in the UCSF specific pathogen–free animal facility in
accordance with the guidelines established by the Institutional
Animal Care and Use Committee and Laboratory Animal Re-
source Center, and all experimental procedures were approved
by the Laboratory Animal Resource Center at UCSF.
T cell differentiation
T cells were enriched from spleen and LNs using the MagniSort
CD4 negative selection kit (Thermo Fisher Scientific). Naive
CD4+ T cells were isolated by flow cytometry based on the
markers CD4+CD62L+CD44−CD25− or using the Easysep mouse
naive T cell isolation kit. 105 naive T cells were cultured for 4 d
(Th1, Th17, iT reg cell) or 5 d (Th2) in a 96-well flat-bottom plate
coated with 2 µg/ml anti-CD3 (clone 2C11; Tonbo) and 2 µg/ml
anti-CD28 (clone 37.51; Tonbo) with the relevant cytokines and
blocking antibodies: Th17 (20 ng/ml IL-6, 2 ng/ml TGFβ, 10 µg/
ml anti-IL4 [clone 11B11; Tonbo], and 10 µg/ml anti-INFγ [clone
XMG1.2; Tonbo]), pathogenic Th17 (20 ng/ml IL-6, 20 ng/ml
IL-1β, 20 ng/ml IL-23, 10 µg/ml anti-IL4, and 10 µg/ml anti-INFγ),
Th1 (20 ng/ml IL-12, 100 U/ml IL-2, and 10 µg/ml anti-IL4), iT
reg cell (20 ng/ml TGFβ and 100 U/ml IL-2), Th2 (500 U/ml IL-4
as supernatant from I3L6 cells [Tepper et al., 1989] or 20 ng/ml
mouse IL-4, 100 U/ml IL-2, and 10 µg/ml anti-INFγ), or Th0 (100
U/ml IL-2). After 3 d of culture, T cells cultured under Th2
conditions were removed from stimulation with anti-CD3/anti-
CD28 and cultured for an additional 2 d with fresh cytokines.
Th17 cultures were performed in Iscove’s medium, Th1/iT reg
cell cultures were performed in RPMI, and Th2 cultures were
performed in Dulbecco’s medium. All media were supplemented
with 10% FBS, penicillin/streptomycin, glucose, pyruvate,
β-mercaptoethanol, and Hepes. Cytokines were purchased from
R&D Systems (murine IL-4, murine IL-6, and human IL-2),
Miltenyi (murine IL-12, murine IL-1β, and murine IL-23), or
HumanKine (human TGFβ). For coculture experiments with
congenically labeled Thy1.1 and Thy1.2 T cells, 5 µg of isotype
control antibody (clone ebioRT IgG2A; Invitrogen) or 5 µg anti-
IL2 (Clone eBio S4B6; Invitrogen) was added to cultures.
Flow cytometry and intracellular staining
LN and spleen were isolated by dissection from mice and then
mashed through a 70-µm filter. Spleen cells were lysed in am-
monium-chloride-potassium lysis buffer to remove red blood
cells. Cells isolated from spleen and LNs were counted, and 1–5 ×
106 cells were first stained in PBS and Ghost Live/Dead (Tonbo),
followed by blocking in 24G2 before staining with the appro-
priate antibodies for flow cytometry. For transcription factor
staining, cells were fixed overnight in the eBioscience Foxp3/
Transcription Factor/Fixation-Concentrate kit (Thermo Fisher
Scientific). After fixation, cells were permeabilized and stained
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with the appropriate antibodies. For ICS, cells were stimulated
for 4 h in Brefeldin A (eBioscience) and eBioscience Cell Stim-
ulation Cocktail (500×). Cells were then fixed and permeabilized
using the BD cytofix/cytoperm kit before staining with the ap-
propriate antibodies.
Antibodies used for flow-cytometry were as follows: PE-Cy7-
conjugated CD4 (clone RM4-5; Tonbo), PE-Cy7-conjugated B220
(clone RA3-6B2; BioLegend), PE-Cy7-conjugated CD62L (clone
MEL-14; Tonbo), PE-Cy7-conjugated CD45 (clone 30-F11; In-
vitrogen), PE-conjugated IL-17A (clone eBio17B7; Invitrogen),
PE-conjugated CD62L (clone MEL-14; Tonbo), PE-conjugated
CD44 (clone IM7; BioLegend), PE-conjugated CD8 (clone 53-6.7;
Tonbo), PE-conjugated RORγ (Q31-378; BD Biosciences), PE-
conjugated IL-13 (clone eBio13A; Invitrogen), FITC-conjugated
Thy1.2 (clone 53-2.1; BD Biosciences), FITC-conjugated IFNγ
(clone xMG1.2; Invitrogen), FITC-conjugated Foxp3 (clone FJK-
16s; Invitrogen), FITC-conjugated CD44 (clone IM7; BioLegend),
FITC-conjugated CD8 (clone 53-6.7; Tonbo), allophycocyanin
(APC)-conjugated Thy1.1 (clone OX-7; BioLegend), APC-
conjugated CD25 (clone PC61.5; Tonbo), APC-conjugated CD4
(clone GK1.5; BioLegend), APC-conjugated IL-2 (clone JES6-5H4;
Invitrogen), APC-conjugated CD62L (clone MEL-14; Tonbo),
PerCP-conjugated CD45 (clone 30-F11; Invitrogen), eFluor 450-
conjugated TCRβ (clone H57-597; Tonbo), eFluor 450-conjugated
CD8 (clone 53-6.7; Tonbo), PerCP-Cy5.5-conjugated CD4 (clone
GK1.5; BioLegend), Ghost UV 450 (Tonbo), and Ghost 510
(Tonbo).
Colitis
Anti-CD3 colitis was performed by injecting 50 µg of anti-CD3
(clone 145-2C11; Tonbo) intraperitoneally. 48 h after injection,
mice were euthanized, and blood was collected by cardiac
puncture, tissue was collected for H&E histology, and IELs were
isolated for flow cytometry. Sample sizes of three to four mice
per genotype were used for each experimental replicate. No
mice were excluded from the study. Rag colitis was performed
by injecting CD4+RBhiCD25−CD44− T cells into Rag1−/− hosts (4 ×
105/200 µl PBS). Weight was monitored weekly for 6 wk.
Lamina propria lymphocytes were isolated for flow cytometry,
and tissue was collected for histology. Histology for colitis was
scored blinded using the following scoring system (Rutz et al.,
2015): 0, no immune cell infiltration; 1, minimal inflammation
with <10% infiltration of the mucosa; 2, mild inflammation,
10–25% of the mucosa infiltrated; 3, moderate inflammation,
26–50% infiltration; 4, extensive infiltration, 51–75% affected;
and 5, diffuse infiltration, >75% of the mucosa infiltrated.
Isolation of small intestine IELs
Peyer’s patches and fat were removed from the small intestine,
and the intestine was cut longitudinally and then into pieces
∼1.0 cm in length. After washing in PBS, the pieces of small
intestine were incubated with vigorous shaking (230 rpm) in
HBSS containing 5% FBS, 10 mMHepes, and 1 mM dithiothreitol
for 30 min at 37°C. After extensive vortexing and filtering
through a 70-µm filter, the flowthrough was spun down at
1,500 rpm for 5 min. The cell pellet was resuspended in 40%
Percoll and then underlaid with 80% Percoll and spun at
2,500 rpm for 20 min with no brake. The interphase containing
the IELs was collected for flow cytometry. Isolated IEL cells were
resuspended in complete RPMI containing Brefeldin A (eBio-
science) and eBioscience Cell Stimulation Cocktail (500×) con-
taining PMA/ionomycin and incubated for 4 h before flow
cytometry for intracellular cytokines. For T reg cell analysis,
isolated IELs were analyzed directly for flow cytometry of Foxp3
expression.
Isolation of colonic lamina propria lymphocytes
Lamina propria lymphocytes were isolated using magnetic-
activated cell sorting with the MACS Lamina Propria Dissocia-
tion Kit (Miltenyi Biotec) following the manufacturer’s protocol.
Briefly, Peyer’s patches and fat were removed from the small
intestine, and the intestine was cut longitudinally and then into
pieces∼1.0 cm in length. After extensive washing and enzymatic
digestion, tissue was homogenized with the gentle MACS Dis-
sociator. Homogenized tissue was filtered through a 100-µm
filter, and flowthrough was spun down at 300 g for 10 min.
The cell pellet containing epithelial cells and lymphocytes was
further enriched using the MagniSort CD4 negative selection kit
(Thermo Fisher Scientific). Isolated T cells were resuspended in
complete RPMI containing Brefeldin A and Cell Stimulation
Cocktail containing PMA/ionomycin and incubated for 4 h be-
fore flow cytometry for intracellular cytokines.
ELISA
Naive T cells were cultured under Th17-inducing conditions for
4 d or with anti-CD3/anti-CD28 for 12 or 24 h, and supernatant
was collected. IL-2, IL-17A, IL-17F, and IL-21 ELISAs were per-
formed using Ready-Set-Go ELISA Kits (eBioscience).
RNA isolation and qPCR
RNA was isolated from T cell cultures using the RNeasy micro
kit (Qiagen). Mouse tissue RNA was isolated by homogeni-
zation in Trizol reagent (Invitrogen). RNA was isolated from
T cell subsets by sorting cells from a Foxp3-GFP mouse based
on the following markers: naive (CD62L+CD44−CD25−),
memory-activated (CD62L−CD44+), and T reg cells (GFP+).
Isolated RNA was reverse transcribed using superscript IV
reverse transcription (Invitrogen) with Oligodt20 primers
(Invitrogen). qPCR was performed on an ABI 7500 fast ma-
chine using Quantabio PerfeCTa qPCR Tough Mix. All re-
actions were normalized to Actin (ActB), and fold induction
was calculated using the ddCT method. All primer-probes
were purchased from ABI: Il17a (Mm00439618_m1), Il17f
(Mm00521423_m1), Il2 (Mm99999222_m1), Atf7ip (Mm004
79827_m1), Rorc (Mm01261022_m1), and ActB (Mm00
607939_s1).
RNA-seq
Total RNA was extracted using Trizol and purified using a
Qiagen microcolumn. Illumina libraries were generated from
total RNA using the Illumina TruSeq Library Prep Kit and se-
quenced on the Illumina HiSeq 4000 to a depth of ≥20 million
reads. Sequence alignment was performed using STAR (version
2.4.2a; Dobin et al., 2013). Mappings were restricted to those that
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were uniquely assigned to the mouse genome, and unique read
alignments were used to quantify expression and aggregated on
a per-gene basis using the Ensembl (GRCm38.78) annotation.
Differentially expressed genes between experimental groups
were then determined using DESeq2 (v1.16.1; Love et al., 2014).
ChIP
ChIP was performed by Active Motif. Primary naive T cells were
fixedwith 1% formaldehyde for 15min and quenchedwith 0.125M
glycine. Chromatin was isolated by the addition of lysis buffer,
followed by disruption with a Dounce homogenizer. Lysates were
sonicated, and the DNA was sheared to an average length of
300–500 bp. Genomic DNA (input) was prepared by treating
aliquots of chromatin with RNase, proteinase K, and heat for de-
cross-linking, followed by ethanol precipitation. Pellets were re-
suspended, and the resulting DNA was quantified on a NanoDrop
spectrophotometer. Extrapolation to the original chromatin vol-
ume allowed quantitation of the total chromatin yield. An aliquot
of chromatin (15 µg) was precleared with protein A agarose beads
(Invitrogen). Genomic DNA regions of interest were isolated using
5 µg of antibody against H3K9me3 (Active Motif; #39161, Lot #2).
Complexes were washed, eluted from the beads with SDS buffer,
and subjected to RNase and proteinase K treatment. Cross-links
were reversed by incubation overnight at 65°C, and ChIP DNAwas
purified by phenol-chloroform extraction and ethanol precipita-
tion. The quality of ChIP-isolated DNA was tested by qPCR. qPCR
reactions were performed in triplicate on specific genomic regions
using SYBR Green Supermix (Bio-Rad). The resulting signals were
normalized for primer efficiency by carrying out qPCR for each
primer pair using input DNA.
ChIP-seq
ChIP-seq and subsequent data analysis was performed by Active
Motif. Illumina sequencing libraries were prepared from the
ChIP and input DNAs by the standard consecutive enzymatic
steps of end-polishing, dA-addition, and adaptor ligation. After a
final PCR amplification step, the resulting DNA libraries were
quantified and sequenced on Illumina’s NextSeq 500 (75-nt
reads, single end). Reads were aligned to the mouse genome
(mm10) using the Burrows-Wheeler Aligner algorithm (default
settings; Li and Durbin, 2009). Duplicate reads were removed,
and only uniquely mapped reads (mapping quality ≥25) were
used for further analysis. Alignments were extended in silico at
their 39 ends to a length of 200 bp, which is the average genomic
fragment length in the size-selected library, and assigned to 32-
nt bins along the genome. The resulting histograms (genomic
“signal maps”) were stored in bigWig files. H3K9me3-enriched
regions were identified using the Spatial Clustering for Identi-
fication of ChIP-Enriched Regions algorithm (spatial clustering
for identification of ChIP-enriched regions; Zang et al., 2009) at
a cutoff of FDR 1 × 10−10 and a max gap parameter of 600 bp.
Peaks that were on the ENCODE (Encyclopedia of DNA Ele-
ments) blacklist of known false ChIP-seq peaks were removed.
Signal maps and peak locations were used as input data to the
ActiveMotifs proprietary analysis program, which creates Excel
tables containing detailed information on sample comparison,
peak metrics, peak locations, and gene annotations.
RNA expression data
The expression levels of Atf7ip were assessed in mouse cells and
tissues using the BioGPS dataset (http://biogps.org/dataset/
GSE10246/), GeneAtlas MOE430, gcrma. A subset of the data
from probeset 1454973, containing only the baseline expression
profiles ofmouse cells and tissues, was used to visualize the gene
expression profile.
Western blot
Extracts for Western blotting were isolated as previously per-
formed (Timms et al., 2016). Five million CD4+ T cells were lysed
in cytoplasmic buffer containing 10 mM Hepes, 1.5 mM MgCl2,
10 mMKCl, 0.5 mM dithiothreitol, EDTA-free protease inhibitor
cocktail, and 0.1% IGEPAL. The nuclear pellet was isolated by
centrifugation at 1,500 rpm for 5 min. The total nuclear extract
was isolated by incubation of the nuclear pellet with 1% SDS and
1:100 benzonase. The nuclear extract was heated in sample
buffer containing SDS for 10 min at 70°C before separation with
SDS-PAGE and transfer to a polyvinylidene fluoride membrane.
The membrane was then blocked with 5% milk in TBST (Tris-
buffered saline and Tween 20) followed by 1-h incubation with
the primary antibody. The membrane was washed 4× for 5 min
in Tris-buffered saline and Tween 20 before incubation in HRP-
conjugated secondary antibody. The membrane was visualized
with ECL reagent (Thermo Fisher Scientific). Antibodies used
forWestern blot were as follows: anti-MACF1 (ab84497; Abcam);
rabbit anti-mouse anti-histone H3 antibody, Nuclear Loading
Control and ChIP Grade (Ab1791; Abcam); rabbit anti-mouse
anti-histone H3 (trimethyl K9) antibody, ChIP Grade (Ab8898;
Abcam), peroxidase affinipure goat anti-rabbit IgG (H+L; 111-
035-144; Jackson ImmunoResearch).
ChIP qPCR
5 × 106 naive T cells were used for each ChIP reaction following
the protocol from the Diagenode LowCell# Chip Kit protein G.
Briefly, cells were lysed and then sonicated for 8 min using a
Covaris s220 sonicator. ChIP was performed using an H3K9me3
antibody from Abcam (ab8898) and an irrelevant IgG control
(Diagenode C15410206). qPCR was performed using SYBR green
with the following primer pairs: Il2/Il21: forward, 59-GGGGCA
GTAACTTCGACTTG-39, and reverse, 59-AGTCGAGCTGAGATG
TGGAA-39; and Zfp780b: forward, 59-AACTGTGTTTGCCGGAGA
TG-39, and reverse, 59-GTCCTGTGCTGGCCATTAAC-39. The
primer concentration per 25-µl qPCR reaction was 200 nM. 5 µl
of ChIP-isolated DNA was used per reaction. Relative Ct values
obtained were normalized against the total input to obtain the
percentage of amplified ChIP DNA per input.
Statistical analysis
All experiments were performed using randomly assigned mice
without investigator blinding. No data were excluded. Statistical
significance between two groups was calculated using an un-
paired, parametric, two-tailed Student’s t test or the non-
parametric Mann–Whitney test. For T cell transfer colitis
experiments, the groups were first compared with two-way
ANOVA followed by multiple comparisons between groups us-
ing multiple t tests (Holm–Sidak method). Experimental groups
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included a minimum of three biological replicates. Intragroup
variationwas not assessed. All statistical analysis was performed
using Prism 7 (GraphPad Software). Figures display means ± SD
unless noted otherwise. A P value <0.05 was considered statis-
tically significant. No statistical methods were used to prede-
termine sample size.
Data availability
RNA-seq and ChIP-seq data are deposited in the Gene Expression
Omnibus under accession nos. GSE131511 and GSE131533.
Online supplemental material
Fig. S1 details creation of the Atf7ip conditional KOmouse. Fig. S2
shows data on T cell proliferation in Atf7ipfl/fl mice and provides
supplementary data for colitis experiments. Fig. S3 provides
qPCR data on genes identified by RNA-seq, data on pathogenic
Th17 differentiation, and supplementary ChIP-seq data.
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